SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

NCT02117167 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

999

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: AZD2014
DRUG: AZD4547
DRUG: AZD5363
DRUG: AZD8931
DRUG: Selumetinib
DRUG: Vandetanib
DRUG: Standard maintenance for squamous NSCLC
DRUG: Pemetrexed
DRUG: Durvalumab
DRUG: savolitinib
DRUG: Olaparib

Sponsor

UNICANCER

Collaborators

[object Object]
[object Object]
[object Object]